MALIGNANT MELANOMA
Clinical trials for MALIGNANT MELANOMA explained in plain language.
Never miss a new study
Get alerted when new MALIGNANT MELANOMA trials appear
Sign up with your email to follow new studies for MALIGNANT MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New vaccine combo shows promise in advanced skin cancer trial
Disease control OngoingThis study tests two experimental cancer vaccines, SCIB1 and iSCIB1+, when added to standard immunotherapy drugs (nivolumab with ipilimumab or pembrolizumab) for people with advanced melanoma that cannot be removed by surgery. The goal is to see if the vaccines are safe and can i…
Matched conditions: MALIGNANT MELANOMA
Phase: PHASE2 • Sponsor: Scancell Ltd • Aim: Disease control
Last updated May 16, 2026 23:47 UTC
-
Brain tumor trial adds radiation to drug cocktail for advanced melanoma
Disease control OngoingThis study tests whether adding targeted radiation (stereotactic radiosurgery) to a three-drug combination (binimetinib, encorafenib, pembrolizumab) helps control melanoma that has spread to the brain. It includes 10 adults with a specific gene mutation (BRAF V600). The main goal…
Matched conditions: MALIGNANT MELANOMA
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated May 16, 2026 23:36 UTC
-
New combo aims to boost immune attack on rare melanoma
Disease control OngoingThis early-phase trial tests whether adding an oral drug (DEC-C) to the immunotherapy nivolumab can help the immune system better fight advanced mucosal melanoma, a rare and hard-to-treat skin cancer. The study includes 8 adults with unresectable or metastatic disease. The main g…
Matched conditions: MALIGNANT MELANOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug combo shows promise for kids with Hard-to-Treat melanoma
Disease control OngoingThis study tested a combination of two drugs (temozolomide and peginterferon alfa-2b) in children and young adults up to age 21 with advanced or recurrent melanoma that cannot be removed by surgery. The main goal was to see how well the tumors responded and to check for side effe…
Matched conditions: MALIGNANT MELANOMA
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 14, 2026 12:05 UTC